Immedica wins accelerated approval for once-rejected rare disease drugnews2026-02-24T14:18:23+00:00February 24th, 2026|Endpoints News|
Fortress to sell priority review voucher for $205Mnews2026-02-23T19:34:21+00:00February 23rd, 2026|Endpoints News|
FDA unveils long-awaited guidance on new pathway for individualized therapiesnews2026-02-23T16:30:45+00:00February 23rd, 2026|Endpoints News|
Vanda gets FDA approval for ‘franchise-extending’ antipsychoticnews2026-02-21T00:51:50+00:00February 21st, 2026|Endpoints News|
Teva beats Corcept in appeals fight over generic Cushing’s syndrome drugnews2026-02-19T19:08:40+00:00February 19th, 2026|Endpoints News|
FDA formalizes one pivotal trial policy via NEJM perspectivenews2026-02-19T16:47:54+00:00February 19th, 2026|Endpoints News|
Senate health committee chair plots future FDA changesnews2026-02-18T20:36:22+00:00February 18th, 2026|Endpoints News|
Reversal on Moderna’s flu application follows atypical path through FDAnews2026-02-18T15:45:05+00:00February 18th, 2026|Endpoints News|
FDA reverses course, will review Moderna’s flu vaccinenews2026-02-18T12:45:45+00:00February 18th, 2026|Endpoints News|
FDA rejects Disc Medicine’s rare disease drug despite granting it a commissioner vouchernews2026-02-17T16:14:16+00:00February 17th, 2026|Endpoints News|
